Home   >  
Cell Cycle/DNA Damage

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
ABC-1183 Chemical Structure
BCP30547 ABC-1183 1042735-18-1
ABC-1183 is a selective dual GSK3α/β and CKD9 inhibitor.
SEL120-34A Chemical Structure
BCP30533 SEL120-34A 1609522-33-9
SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
BSJ-03-123 Chemical Structure
BCP30504 BSJ-03-123 BSJ-03-123
BSJ-03-123 is a potent and novel CDK6-selective small-molecule degrader (PROTAC).
dBET6 Chemical Structure
BCP30500 dBET6 1950634-92-0
dBET6 is a novel degrader of BET bromodomain proteins. dBET6 prompts a collapse of global elongation that phenocopies CDK9 inhibition.
Atuveciclib Racemate Chemical Structure
BCP30202 Atuveciclib Racemate 1414943-88-6
Atuveciclib Racemate is the racemate mixture of BAY-1143572. BAY-1143572 is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
CDK4-IN-1 Chemical Structure
BCP12704 CDK4-IN-1 1256963-02-6
CDK4-IN-1 is a selective inhibitor of cyclin-dependent kinase 4.
THZ1 2HCl Chemical Structure
BCP29892 THZ1 2HCl THZ12HCl
THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.
Riviciclib Chemical Structure
BCP17903 Riviciclib 920113-02-6
Riviciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation.
(+/-)-Roscovitine Chemical Structure
BCP19053 (+/-)-Roscovitine 186692-44-4
Roscovitine is a potent and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
CGP74514A Chemical Structure
BCP20240 CGP74514A 190653-73-7
CGP74514A is a CDK1 inhibitor with potential anticancer activity.
123下一页末页共 91 条记录 1 / 10 页